145 related articles for article (PubMed ID: 12005203)
1. Antithrombotic and platelet function inhibiting effects of ML3000, a new antiinflammatory drug with Cox/5-LOX inhibitory activity.
Tries S; Laufer S; Radziwon P; Breddin HK
Inflamm Res; 2002 Mar; 51(3):129-34. PubMed ID: 12005203
[TBL] [Abstract][Full Text] [Related]
2. The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2.
Tries S; Neupert W; Laufer S
Inflamm Res; 2002 Mar; 51(3):135-43. PubMed ID: 12005204
[TBL] [Abstract][Full Text] [Related]
3. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.
Rotondo S; Krauze-Brzósko K; Manarini S; Evangelista V; Cerletti C
Eur J Pharmacol; 2004 Mar; 488(1-3):79-83. PubMed ID: 15044038
[TBL] [Abstract][Full Text] [Related]
4. The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy.
Celotti F; Durand T
Prostaglandins Other Lipid Mediat; 2003 Jul; 71(3-4):147-62. PubMed ID: 14518558
[TBL] [Abstract][Full Text] [Related]
5. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.
Schrör K
Semin Thromb Hemost; 1997; 23(4):349-56. PubMed ID: 9263351
[TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory activity of myricetin-3-O-beta-D-glucuronide and related compounds.
Hiermann A; Schramm HW; Laufer S
Inflamm Res; 1998 Nov; 47(11):421-7. PubMed ID: 9865500
[TBL] [Abstract][Full Text] [Related]
7. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile.
Argentieri DC; Ritchie DM; Ferro MP; Kirchner T; Wachter MP; Anderson DW; Rosenthale ME; Capetola RJ
J Pharmacol Exp Ther; 1994 Dec; 271(3):1399-408. PubMed ID: 7996452
[TBL] [Abstract][Full Text] [Related]
8. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of 5-lipoxygenase and cyclooxygenases 1 and 2 by ML3000 reduces joint destruction in adjuvant arthritis.
Gay RE; Neidhart M; Pataky F; Tries S; Laufer S; Gay S
J Rheumatol; 2001 Sep; 28(9):2060-5. PubMed ID: 11550975
[TBL] [Abstract][Full Text] [Related]
10. Focused antithrombotic therapy: novel anti-platelet salicylates with reduced ulcerogenic potential and higher first-pass detoxification than aspirin in rats.
Hung DY; Mellick GD; Masci PP; Whitaker AN; Whitehouse MW; Roberts MS
J Lab Clin Med; 1998 Dec; 132(6):469-77. PubMed ID: 9851736
[TBL] [Abstract][Full Text] [Related]
11. Effects of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine on platelet aggregation and thrombosis in experimental animals.
Momo K; Someya K; Tachiiri T; Mitsuoka Y; Nakamura K; Imai S; Ino T; Ohkubo H
Arzneimittelforschung; 1992 Jan; 42(1):32-9. PubMed ID: 1586377
[TBL] [Abstract][Full Text] [Related]
12. Neferine exerts its antithrombotic effect by inhibiting platelet aggregation and promoting dissociation of platelet aggregates.
Zhou YJ; Xiang JZ; Yuan H; Liu H; Tang Q; Hao HZ; Yin Z; Wang J; Ming ZY
Thromb Res; 2013 Aug; 132(2):202-10. PubMed ID: 23773522
[TBL] [Abstract][Full Text] [Related]
13. 2',5'-Dihydroxychalcone as a potent chemical mediator and cyclooxygenase inhibitor.
Lin CN; Lee TH; Hsu MF; Wang JP; Ko FN; Teng CM
J Pharm Pharmacol; 1997 May; 49(5):530-6. PubMed ID: 9178190
[TBL] [Abstract][Full Text] [Related]
14. Antithrombotic effects in a rat model of aspirin-insensitive arterial thrombosis of desethyl KBT-3022, the main active metabolite of a new antiplatelet agent, KBT-3022.
Shimazawa M; Takiguchi Y; Umemura K; Kondo K; Nakashima M
Eur J Pharmacol; 1997 Jun; 328(2-3):183-9. PubMed ID: 9218700
[TBL] [Abstract][Full Text] [Related]
15. ASP6537, a novel highly selective cyclooxygenase-1 inhibitor, exerts potent antithrombotic effect without "aspirin dilemma".
Sakata C; Kawasaki T; Kato Y; Abe M; Suzuki K; Ohmiya M; Funatsu T; Morita Y; Okada M
Thromb Res; 2013 Jul; 132(1):56-62. PubMed ID: 23522855
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic activity of the phosphodiesterase III inhibitor pelrinone in a canine model of coronary artery thrombosis: enhancement of efficacy with concurrent alpha 2-adrenergic antagonism.
Kitzen JM; McCallum JD; Harvey C; Morin ME
J Cardiovasc Pharmacol; 1991 Dec; 18(6):777-90. PubMed ID: 1725888
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effect of curcumin, a food spice from turmeric, on platelet-activating factor- and arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca2+ signaling.
Shah BH; Nawaz Z; Pertani SA; Roomi A; Mahmood H; Saeed SA; Gilani AH
Biochem Pharmacol; 1999 Oct; 58(7):1167-72. PubMed ID: 10484074
[TBL] [Abstract][Full Text] [Related]
18. Protective effect of Foeniculum vulgare essential oil and anethole in an experimental model of thrombosis.
Tognolini M; Ballabeni V; Bertoni S; Bruni R; Impicciatore M; Barocelli E
Pharmacol Res; 2007 Sep; 56(3):254-60. PubMed ID: 17709257
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.
Catella-Lawson F; Reilly MP; Kapoor SC; Cucchiara AJ; DeMarco S; Tournier B; Vyas SN; FitzGerald GA
N Engl J Med; 2001 Dec; 345(25):1809-17. PubMed ID: 11752357
[TBL] [Abstract][Full Text] [Related]
20. Licofelone, a dual lipoxygenase-cyclooxygenase inhibitor, downregulates polymorphonuclear leukocyte and platelet function.
Rotondo S; Dell'Elba G; Krauze-Brzósko K; Manarini S; Martelli N; Pecce R; Evangelista V; Cerletti C
Eur J Pharmacol; 2002 Oct; 453(1):131-9. PubMed ID: 12393068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
